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Abstract
The treatment of hepatitis C virus (HCV) infection by combination of direct acting antivirals
(DAA), with different mode of action, has made substantial progress in the past few years.
However, appearance of resistance and high cost of the therapy is still an obstacle in the
achievement of the therapy, more specifically in developing countries. In this context, search
for affordable antivirals with new mechanisms of action is still needed. Tea, after water, is
the most popular drink worldwide. Polyphenols extracted from green tea have already
shown anti-HCV activity as entry inhibitors. Here, three different theaflavins, theaflavin
(TF1), theaflavin-3’-monogallate (TF2), and theaflavin-3-3’-digallate (TF3), which are major
polyphenols from black tea, were tested against HCV in cell culture. The results showed that
all theaflavins inhibit HCV infection in a dose-dependent manner in an early step of infection.
Results obtained with HCV pseudotyped virions confirmed their activity on HCV entry and
demonstrated their pan-genotypic action. No effect on HCV replication was observed by
using HCV replicon. Investigation on the mechanism of action of black tea theaflavins
showed that they act directly on the virus particle and are able to inhibit cell-to-cell spread.
Combination study with inhibitors most widely used in anti-HCV treatment regimen demon-
strated that TF3 exerts additive effect. In conclusion, theaflavins, that are present in high
quantity in black tea, are new inhibitors of HCV entry and hold promise for developing in
therapeutic arsenal for HCV infection.
Introduction
Hepatitis C caused by hepatitis C virus (HCV) has been called silent epidemic. The majority of
infections are asymptomatic, but in 20% of cases the virus persists, leading to chronic hepatitis
[1] causing liver fibrosis and cirrhosis, which is often a prelude to hepatocellular carcinoma
[2]. Liver transplantation is often necessary in a portion of HCV infected patients [3]. Tremen-
dous efforts have been expended to develop efficacious prophylactic and therapeutic treatment
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regimen for chronic hepatitis C. No vaccine is available due, at least in part, to the high geno-
mic variability of HCV, which has led to the distinction of seven genotypes, most of which
have multiple subtypes [4]. The therapeutic option against HCV has recently been improved
with the development of HCV direct acting antivirals (DAA) like Daclatasvir, Sofosbuvir and
Simeprevir, targeting viral proteins NS5A, NS5B polymerase or NS3/4A protease, respectively
[5]. These approved DAA prominently increase the sustained viral response (SVR) up to ~95%
in most patients, depending primarily on disease stage and the genotype of the infecting virus
[5]. However, treatment with DAAs is not without limitation; it is associated with side-effects,
resurgence of infection in transplant patient and high cost especially in developing countries
[6,7]. Approved DAAs mainly target the virus replication leading to emergence of resistance
mutations in this RNA virus genome [8]. Thus, novel combinations of low cost entry inhibi-
tors with conventional treatment targeting different stages of the HCV life cycle, may provide
a promising approach against HCV drug resistance development and infection relapse [9].
Moreover, prevention of donor liver re-infection by inhibiting viral entry into hepatocytes
might be achieved using DAAs targeting entry.
Hepatitis C virus is an enveloped positive-stranded RNA virus encoding a polyprotein, co-
and post-translationnally cleaved into structural and non-structural proteins [10]. Two viral
glycoproteins E1 and E2 are part of the lipoviroparticle envelope. Non-structural proteins,
NS2 to NS5B, are involved in replication and assembly of new virions. Actual antiviral therapy
with DAA targets three non-structural proteins, the RNA-dependent RNA polymerase NS5B,
a non-enzymatic protein involved in replication and assembly of HCV NS5A, and the viral
protease NS3/4A, involved in polyprotein processing and essential for viral replication [11].
Virus entry into hepatocytes is a multistep process that involves attachment of the particle to
glycosaminoglycans and subsequent binding to entry factors, SR-B1, CD81, Claudin-1 and
Occludin [12]. After clathrin-mediated endocytosis and fusion of the viral envelope to endoso-
mal membrane, the viral RNA is replicated, assembled and released via the secretory pathway.
In recent times, a wide variety of natural compounds have been extensively studied in
terms of their antiviral activity [13]. Polyphenols are one such group of compounds with
potent antiviral activities. Earlier studies of others and our group have shown that epigallocate-
chin-3-gallate (EGCG), a major green tea polyphenol, inhibits HCV entry by a new mecha-
nism of action [14–16]. Recently, black tea polyphenols, theaflavins (TFs), components of
black tea extract, have shown potent antiviral activities against calcivirus [17], herpes simplex
virus 1 (HSV-1) [18], human immunodeficiency virus 1 (HIV-1) [19] and influenza A [20].
Theaflavins are formed by the enzymatic oxidation and decarboxylation of catechins during
the manufacture of black tea [21]. The most abundant TFs are theaflavin (TF1), theaflavin-3’-
monogallate (TF2) and theaflavin-3-3’-digallate (TF3). Theaflavins share many of the struc-
tural characteristics of EGCG, which prompted us to screen theaflavins against HCV. We also
aim to identify compounds with enhanced anti-HCV activity than previously studied com-
pounds to boost the development of suitable inhibitors.
Here, we report the capacity of theaflavins to inhibit HCV infection in vitro, demonstrating
their activity on HCV entry. Given the abundance of theaflavins, especially in tea growing
areas, and popularity of tea as a drink next only to water and as health drink, the compounds
hold promise for developing in therapeutic arsenal for HCV infection.
Materials and methods
Chemicals and antibodies
DMEM, goat and fetal bovine sera were purchased from Invitrogen (Carlsbad, CA). 4’,6-dia-
midino-2-phenylindole (DAPI) was from Molecular Probes (Invitrogen). EGCG used as a
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control was from Calbiochem (Merck Chemicals, Darmstadt, Germany). Theaflavin 3’-mono-
gallate (TF2P) and theaflavin 3,3’-digallate (TF3P) used to compare with our extracted theafla-
vins, TF2 and TF3, were from PhytoLab (Germany). Boceprevir was kindly provided by
Philippe Halfon (Hôpital Européen, Laboratoire Alphabio, Marseille, France). Sofosbuvir
(PSI-7977) and Daclatasvir (BMS-790052) were purchased from Selleckchem (Houston, USA).
All other chemicals like DMSO were purchased from Sigma. Mouse anti-E1 monoclonal anti-
body (MAb) A4 was produced in vitro [22]. Mouse anti-GFP (Roche) and mouse anti-β tubu-
lin monoclonal antibody (TUB 2.1) were from Sigma. Peroxidase-conjugated goat anti-mouse
IgG and Cy3-conjugated goat anti-mouse IgG were from Jackson Immunoresearch (West
Grove, PA).
Cells and virus strains
Human hepatoma Huh-7 cells and human embryonic kidney HEK 293T cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with glutamax-I and 10% fetal
bovine serum.
Japanese fulminant hepatitis-1 (JFH-1) HCV strain containing titer enhancing mutations
[23] was used. Virus stocks were prepared by infecting Huh-7 cells with HCV JFH-1 (HCVcc)
with a titer of 106 pfu/ml.
Theaflavins extraction and stock preparation
Theaflavins were extracted with ethyl acetate from prepared “crush tear curl” (CTC), black tea
from Assam, India. The enriched theaflavin extract was subjected to sephadex LH-20 column
(Sigma) and eluted with 40% acetone solution. The elute with distinguished reddish colours
for each of TF1, TF2 and TF3 was fractionated. Three fractions of theaflavins were concen-
trated by a rotary evaporator and lyophilized, then recrystallized with dehydrated ethanol. The
degree of purity and the mass of the three theaflavins obtained (theaflavin TF1, theaflavin-
3-gallate TF2, theaflavin-3,3’-digallate TF3) were confirmed by UPLC-ESI-MS (S1 Fig). Ultra-
High Performance Liquid Chromatography (UHPLC) analyses were carried out using an
Acquity UPLC H-Class Waters system (Waters, Guyancourt, France) equipped with a diode
array detector (DAD) and an Acquity QDa ESI-Quadrupole Mass Spectrometer. The station-
ary phase was a Waters Acquity BEH C18 column (2,1 x 50 mm, 1,7 μm) connected to a
0.2 μm in-line filter. The mobile phase consisted of 0.1% formic acid in water, and of 0.1% for-
mic acid in acetonitrile. The gradient of acetonitrile was: 10% (0–1 min), 10–100% (1–7 min),
100% (7–9 min) at 0.3 ml/min. Column temperature was set at 30˚C. The samples were dis-
solved in MeOH/H2O (50:50) at the concentration of 500 μg/ml. Injection volume was 2 μl.
The ionization was performed in negative mode. Cone voltage was set at 30V. Probe Tempera-
ture was 600 ˚C. Capillary voltage was 0.8kV. The MS-Scan mode was used from 200 to 950
Da.
The fraction enriched in TF1, the mixed TF1, TF2 and TF3, and purified TF3 were each dis-
solved in DMSO to produce stock solutions at a concentration of 250 mg/ml.
Cytotoxicity assay
Huh-7 cells were seeded in 96 well plates and incubated at 37˚C for 24 h. Cultures of 60–70%
confluency were treated with various concentrations of theaflavins. An MTS [3-(4,
5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt] based assay (CellTiter 96 aqueous nonradioactive cell proliferation assay, Promega)
was used to evaluate cell viability treated after 24, 48 and 72 h. DMSO was used as control.
Theaflavins inhibit hepatitis C virus entry
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Immunofluorescence assay for anti-HCV quantification in confocal
microscopy
Huh-7 cells were seeded in 96-well plates (6.000 cells/well) the day before infection. Cells were
infected for 2 h with HCVcc at a multiplicity of infection (MOI) of 0.8. Then, the inoculum
was removed and cells were overlaid with fresh medium. After 30 h, cells were fixed with ice-
cold methanol and were processed for immunofluorescent detection of E1 envelope protein as
described [24]. Nuclei were stained with 1 μg/ml DAPI. Confocal images were recorded using
an automated confocal microscope InCell Analyzer 6000 (GE Healthcare Life Sciences). Each
image was then processed using the Colombus image analysis software (Perkin Elmer) as
described [14].
Viral RNA quantification
Huh-7 cells seeded in 12-well plates were inoculated with HCVcc for 2h. The inoculum was
removed and replaced with culture medium. Forty-eight hours after infection, cells were lysed
in lysis buffer from the kit NucleoSpin RNA Plus (Macherey Nagel), and total RNA extracted
following manufacturer’s instructions, eluted in a final volume of 60 μl of H2O, and quantified.
Ten microliters of RNA were used for cDNA synthesis using High Capacity cDNA Reverse
Transcription kit (Applied Biosystems). Five microliters of cDNA were used for real-time
reverse-transcription polymerase chain reaction (qRT-PCR) assay using Taqman probes as
described previously [25].
Detection of E1 glycoprotein by Western blot
Huh-7 cells seeded in 12-well plates were inoculated with HCVcc for 2h. The inoculum was
removed and replaced with culture medium. Forty-eight hours after infection, cells were lysed
in ice cold PBS containing Triton-100 1% and protease inhibitors for 20 min. Cell lysates were
collected and insoluble debris were removed by centrifugation. 20 μg of proteins were analyzed
by western blotting using anti-E1 and anti-β tubulin antibodies. Peroxidase-conjugated goat
anti-mouse secondary antibody (Jackson Immunoresearch) was used for the revelation using
ECL western blotting substrate (Thermo Fischer Scientific).
Time of addition assay
Compounds were added before, during and after inoculation of Huh-7 cells with HCVcc.
Briefly, cells were incubated in the presence or absence of compounds (pretreatment) for 1 h
and subsequently replaced with virus for 1 h (inoculation). Inoculum was removed and
replaced with DMEM for 28 h (post-inoculation). After 30 h cells were fixed and immunofluo-
rescence detection was performed as described above.
Direct effect on viral particle
HCV was pre-incubated with 25 μg/ml of theaflavins for 1 h before inoculation, and then the
mixture was diluted 10 times before being used for the inoculation (1 h at 37˚C), leading to a
final concentration of theaflavins of 2.5 μg/ml. In parallel, Huh-7 cells were inoculated with
HCV in the presence of theaflavins either at 2.5 or 25 μg/ml. Importantly, the MOI was kept
constant in all the conditions. Inoculum was removed and replaced with DMEM. After 30 h,
immunofluorescence was performed as described above.
Theaflavins inhibit hepatitis C virus entry
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Entry assay with HCV pseudo-particles (HCVpp)
The luciferase-based HCV pseudotyped retroviral particles were generated as previously
described [26]. Briefly, HEK-293T cells were transfected with plasmids encoding HCV envelope
proteins, Gag/Pol, and firefly luciferase. The HCV envelope plasmids included 6 different geno-
types (1b, 2a, 3a, 4, 5 and 6). The supernatants of the transfected cells were collected 72 h later
and filtered through a 0.45-μm membrane. Vesicular stomatitis virus pseudoparticles (VSVpp)
were used as a control. For the entry assay, Huh-7 cells were seeded on 96-well plates overnight
and incubated with HCVpp for 2 h at 37˚C in the presence or not of theaflavins. Inoculum was
replaced by DMEM and kept for 48 h. HCVpp entry into Huh-7 cells was measured by lucifer-
ase activity quantification using Luciferase Assay Kit (Promega) and a Berthold luminometer.
HCV replicon and replication assay
The plasmid pSGR-JFH1 encoding a sub-genomic replicon of JFH-1 strain was obtained from
Dr T Wakita [27]. A BglII and an NsiI restriction sites were inserted between codons Pro419
and Leu420 of NS5A, and the coding sequence of enhanced green fluorescent protein (EGFP)
was then inserted between these two sites. This position was previously shown to accept a GFP
insertion in a sub-genomic replicon of the Con1 strain [28]. The plasmid was in vitro tran-
scribed before electroporation into Huh-7 cells. Cells that express replicon were selected for
using 500 μg/mL of geneticin during 15 days and cultured in a medium containing 250 μg/mL
of geneticin. Huh-7 cells stably expressing replicon were seeded in 24-well plates and incu-
bated with the different compounds for 24, 48 and 72 h. They were lysed in ice cold lysis buffer
(Tris HCl 50mM, NaCl 100 mM EDTA 2 mM Triton-100 1% SDS 0.1%) containing protease
inhibitors for 20 min. Cell lysates were collected and insoluble debris were removed by centri-
fugation. 20 μg of proteins were analyzed by western blotting using anti-GFP and anti-β tubu-
lin antibodies. Peroxidase-conjugated goat anti-mouse secondary antibody (Jackson
Immunoresearch) was used for the revelation using ECL western blotting substrate (Thermo
Fischer Scientific).
Cell-to-cell transmission assay
Huh-7 cells were infected with HCVcc at MOI of 0.01. After 2 hours of contact, the inoculum
was removed and replaced with fresh DMEM containing TF1, TF2, TF3 at 25 μg/ml or DMSO
along with neutralizing antibody mAb 3/11 to prevent infection via the cell culture medium.
The cells were propagated for another 72 h prior to immunofluorescence staining as described
above. Quantification was done in 3 independent wells by taking independent pictures of dif-
ferent field of each well.
Statistical analysis
The statistical test used is a Kruskal Wallis nonparametric test followed by a Dunn’s multicom-
parison post hoc test with a confidence interval of 95% to identify individual difference
between treatments. P values < 0.05 were considered as significantly different from the con-
trol. The data were analyzed using Graph Pad Prism (Version 5.0b) by comparisons between
each treated group and untreated group (DMSO control).
Results
Theaflavins inhibit HCV infection
We and others have shown that EGCG, the major polyphenol present in green tea extract, was
active against HCV infection [15,16,29], but no data are available on black tea polyphenols. In
Theaflavins inhibit hepatitis C virus entry
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this context, three theaflavin derivatives (theaflavin TF1, theaflavin-3-gallate TF2 and theafla-
vin-3,3’-digallate TF3) were extracted from CTC Assam black tea and identified by
UPLC-UV-MS (Fig 1) with retention times of 3.82, 3.92, and 3.96 min, respectively (S1 Fig).
The average molecular weight of TF1 (564.49 g/mole), TF2 (716.59 g/mole) and TF3 (868.709
g/mole) was used for calculating the molar concentration of theaflavins which were generally
used in micrograms in the experiments. However, the degree of purity of the compounds is
not at the same level. Theaflavin-3,3’-digallate (TF3) is pure with a degree of purity superior to
97%. By contrast, TF2 which is present as two isomers, theaflavin-3-monogallate and theafla-
vine-3’-monogallate, is in mixture with TF1 and TF3 in the fraction purified (S1 Fig).
The inhibitory activity of theaflavins against HCV infectivity was carried out in dose-
response experiment. Huh-7 cells were infected with HCV strain JFH1 in the presence of
increasing concentrations of theaflavins, 0 to 100 μg/ml. Quantification of infected cells by
immunofluorescence labeling of E1 envelope protein showed significantly decreased infectiv-
ity of HCV in the presence of each three theaflavins, with a clear dose-dependent inhibitory
effect (Fig 2A). The half effective concentration (EC50) was calculated for each molecule to be
17.89, 4.08, and 2.02 μM for TF1, TF2 and TF3, respectively (Table 1). TF3 is the most active.
To confirm that the activity is due to the molecule, a commercial TF3 (TF3P) was tested and
its antiviral activity compared to natural TF3 extracted from black tea. Similar results were
obtained with a calculated EC50 of 4.96 μM for the commercial TF3 (Fig 2A, Table 1). Because
TF2 was difficult to purify and is mixed with TF1 and TF3, a commercial TF2 was also tested,
TF2P, and confirmed the antiviral activity of TF2 against HCV, EC50 = 18.06 (Table 1). Antivi-
ral activity of the different theaflavins was confirmed by the quantification of viral RNA and
viral E1 glycoprotein in Huh-7 cells inoculated with HCVcc in the presence of the molecules.
More than 1 log10 decrease of HCV RNA was observed after treatment with theaflavins, similar
to the decrease observed with EGCG, an inhibitor of HCV entry (Fig 2B). Boceprevir, an NS3
protease inhibitor showed a higher decrease in RNA level due to its mode of action on HCV
replication. Similarly, E1 envelope glycoprotein levels determined by Western blotting were
also decreased in the presence of the theaflavins and the control compounds (Fig 2C). All the
results confirmed that TF1 is the less active and TF3 the most active. We then tested the effect
of theaflavins on cell viability by treating Huh-7 with a range of theaflavin concentrations that
were used in inhibition experiments, 0 to 250 μg/ml, with three different exposure times, 24,
48 and 72 h (Fig 2D–2F). Theaflavins did not decrease cell viability up to 100 μg/ml after short
(24 h) to long (72 h) exposure times, a concentration much higher than the active antiviral
concentrations. The half-medium cytotoxic concentration (CC50) at 72h is estimated to be
250 μg/ml, giving a selective index (SI) of 24, 85 and 142 for TF1, TF2 and TF3, respectively
(Table 1). TF3 is the most promising molecule.
Theaflavins inhibit HCV entry and not replication
The HCV infection cycle is a multistep process that involves entry of the virus into the cell,
replication of the genomic RNA and assembly/release of viral particles. To determine at which
step the different theaflavins exert their action, a time of addition experiment was performed.
The compounds were added before, during or after inoculation of HCV to Huh-7 cells.
EGCG, an inhibitor of HCV entry, and Boceprevir, a HCV NS3 protease inhibitor, were used
as controls. The result clearly demonstrates a significant inhibition of HCV only in the pres-
ence of theaflavins added during inoculation, like EGCG (Fig 3A). There was no inhibition
when compounds were added to cells prior to the infection or post-infection. As expected,
Boceprevir inhibits the post-inoculation step, corresponding to replication. These results,
Theaflavins inhibit hepatitis C virus entry
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taken together, suggest that theaflavins act at an early step of the viral infectious cycle, most
probably the entry step.
Viral pseudoparticles are good models for entry inhibitor assay and also for screening
against different viral genotypes [30]. To confirm that theaflavins act at the entry step, HCVpp
were produced and inoculated to Huh-7 cells in the presence of each theaflavins at active con-
centrations (EC50 and 10 × EC50). Envelope glycoproteins of different HCV genotypes were
used, genotype 1b, 2a, 3a, 4, 5 and 6. The result shows that all the theaflavins inhibit infection
of HCVpp in a dose dependent manner (Fig 3B–3D) confirming their activity on HCV entry.
Moreover, the antiviral activity of each theaflavin is pan-genotypic, with an inhibition of infec-
tion for all HCV genotype tested. HCVpp of genotype 3a are less inhibited by theaflavins than
HCVpp of other genotypes, even if TF3 seems more active on this genotype than TF1 or TF2.
Results presented in Fig 3A suggest that theaflavins are not active on HCV replication
because no inhibitory effect was observed when the compounds were added during the 28 h
post-inoculation. To confirm this data, HCV subgenomic replicon containing a GFP-tagged
NS5A was used. Replicon cells were incubated with TF1, TF2 or TF3 at 25 μg/ml, or Bocepre-
vir at 1 μM, for 72 h, and NS5A protein quantified by Western blot analysis. As expected,
NS5A protein appears as two bands, P56 and P58. The result shows that the replication of the
replicon is not affected by the presence of any of the theaflavins but is inhibited by Boceprevir
(Fig 4). Taken together, our results show the TF1, TF2 and TF3 are inhibitors of HCV entry
and not replication.
Theaflavins act directly on the viral particle
Theaflavins can inhibit HCV entry by acting either directly on the viral particle or on cellular
factors. This second hypothesis seems unlikely because no effect of theaflavins on HCV infec-
tion was observed when cells were pre-treated with the molecules before infection (Fig 3A). To
determine if theaflavins act directly on the viral particle, HCV viral stocks were incubated with
the compounds at 25 μg/ml prior inoculation. The viral stocks containing the compounds
were then diluted 10 times before inoculation leading to a final concentration of theaflavins of
2.5 μg/ml for the inoculation step. In parallel, cells were inoculated with a non-treated virus in
the presence of the compounds at the two different concentrations, 2.5 and 25 μg/ml. As
shown in Fig 5, the inhibitory effect of theaflavins on pre-incubated virus is similar to the one
observed when virus is inoculated on cells at high concentration (25 μg/ml), demonstrating
that theaflavins act directly on HCV particle before entry.
Fig 1. Chemical structures of theaflavins extracted from black tea.
https://doi.org/10.1371/journal.pone.0198226.g001
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Theaflavins inhibit HCV cell-to-cell propagation
HCV infection can follow two different modes of transmission, either by direct entry into the
cell via extracellular medium or via cell-to-cell spread between two neighboring cells. This last
mode of transmission is resistant to neutralizing antibodies and seems to be a major way of
HCV infection [31]. Therefore, it is important to identify antiviral agents able to block cell-to-
cell transmission. To determine if theaflavins can inhibit HCV cell-to-cell spread, Huh-7 cells
were infected with HCVcc with no inhibitor, at low MOI to visualize foci, and further
Fig 2. Theaflavins inhibit HCV infection. (A) Huh-7 cells were inoculated with HCV JFH-1 in the presence of given
concentration of the different theaflavins, TF1, TF2, TF3 and a commercial TF3 (TF3P). Inoculum was removed and
replaced with medium containing theaflavins. Cells were fixed at 30 h post-infection and subjected to
immunofluorescence to quantify number of infected cells. Results are expressed relative to DMSO control without
theaflavins (100%). Huh-7 cells were inoculated with HCV JFH-1 in the presence of the different theaflavins, TF1, TF2
and TF3 at 25 μg/ml, or EGCG at 50 μM, or boceprevir at 1nM. Inoculum was removed and replace with medium
without compounds except for boceprevir. 48h after infection cells were lysed and RNA or proteins extracted.
Quantification of viral RNA by qRT-PCR was performed (B). HCV envelope E1 protein was detected using specific
antibody (A4) as well as ß-tubulin in cellular extracts by Western blot analysis (C). Huh-7 cells were incubated with
given concentrations of TF1 (D), TF2 (E) or TF3 (F) at different concentrations during 24, 48 or 72 h. Cell viability was
measured using an MTS-based assay. Optical density at 490 nm was measured at the different time points. Results are
expressed as mean ± SEM (error bars) of three independent experiments performed in triplicates and relative to
control conditions without compounds.
https://doi.org/10.1371/journal.pone.0198226.g002
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incubated with theaflavins in the presence of neutralizing antibodies to prevent extracellular
infection. 72 h post-infection, the number of cells in the foci were quantified. The results
shows that TF1, TF2 and TF3 significantly reduce number of cells in the foci meaning reduc-
tion in cell-to-cell spread (Fig 6), like EGCG a known inhibitor of cell-to-cell transmission
[15]. This shows that theaflavins are potent inhibitors of both HCV modes of entry.
Combination of theaflavins with replication inhibitors used in hepatitis C
therapy
Finally, in order to determine the potential use of these compounds in antiviral therapy, we
interrogated the effect of theaflavins in combination with the known DAA Sofosbuvir and
Daclatasvir, two inhibitors of HCV replication that target HCV proteins NS5B and NS5A
respectively [32,33]. In the experiment, TF3, the most active theaflavin, was added at different
concentrations along with Sofosbuvir or Daclatasvir at fixed concentration during infection of
Huh-7 cells with HCVcc. The result shows that TF3 can increase the antiviral activity of both
Sofosbuvir and Daclatasvir in an additive manner (Fig 7) demonstrating that it could be use in
combination with DAA used in hepatitis C therapy.
Discussion
The present study identified new entry inhibitors of HCV, theaflavins, the major black tea
polyphenols. Theaflavins inhibit all HCV genotypes and most probably induce inactivation of
the viral particle before inoculation. Interestingly, they are also able to inhibit cell-to-cell
spread of HCV, a major route of infection allowing evasion of the virus from neutralizing anti-
bodies [31]. Moreover, an additive action of TF3 in combination with molecules used for hepa-
titis C therapy was observed.
HCV is transmitted between hepatocytes via classical cell entry but also uses direct cell-to-
cell transfer to infect neighboring hepatocytes. Cell-to-cell transmission was also shown to
play an important role in dissemination and maintenance of resistant variants in cell culture
models [34]. HCV entry is highly orchestrated and essential in initiating viral infection and
spread. This step represents a potential target for HCV inhibitors [35,36] but, up to now, no
HCV entry inhibitor has been marketed, and few are in preclinical trial. The currently used
therapy of DAA regimen cures more than 90% of infected patients, but the appearance of viral
resistance, and recurrence of infection particularly in transplant patients is still a major limita-
tion [37]. Entry inhibitors given along with the DAAs would be expected to exhibit a synergis-
tic effect [35,36]. The present study supported this hypothesis when theaflavin and Sofosbuvir
or Daclatasvir were added in combination and showed additive effect against HCV. This may
lead to pivotal implication in therapeutic regimen of HCV especially because Sofosbuvir, in
Table 1. EC50, CC50 and SI of the different theaflavins.
EC50 CC50
a SI
TF1 17.89 μM (10.09 μg/ml) 442.8 μM (250 μg/ml) 24.7
TF2 4.08 μM (2.92 μg/ml) 348.8 μM (250 μg/ml) 85.5
TF3 2.02 μM (1.75 μg/ml) 287.7 μM (250 μg/ml) 142.4
TF2P 18.06 μM (12.92 μg/ml) ndb
TF3P 4.96 μM (4.30 μg/ml) ndb
a CC50 is estimated after 72h of exposure to the cells.
b not determined
https://doi.org/10.1371/journal.pone.0198226.t001
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combination with other drugs, is a part of all first-line treatments for HCV, and also of some
second-line treatments [37].
HCV treatment efficacy is influenced by infected viral genotype; therefore, treatment regi-
men is dependent on genotypes infected. Our study with HCVpp of different genotypes (1–6)
showed dose-dependent inhibition of HCV by theaflavins (Fig 3B–3D). This represents an
important hit for further drug development.
Fig 3. Theaflavins inhibit HCV entry in a pan-genotypic manner. (A) Huh-7 cells were inoculated with HCV JFH-1
for 2 h and fixed at 30 h post-infection to quantify the number of infected cells. Theaflavins, at 25 μg/ml were either
added for 2 h to the cells before infection (step 1), or during inoculation (step 2), or during the 28 h after inoculation
(step 3), or during the 3 steps (step 1+2+3). EGCG at 50 μM or Boceprevir at 1 μM were added either during the
inoculation step or post-inoculation respectively. (B-D) Huh-7 cells were inoculated with HCVpp of the given
genotypes or VSVpp in the absence (0) or presence of theaflavins at 2.5 or 25 μg/ml. Cells were lysed 48h after infection
and luciferase activity quantified. Results are expressed as mean ± SEM (error bars) of 3 independent experiments
performed in triplicate. Data are normalized to the DMSO, which is expressed as 100% infection.
https://doi.org/10.1371/journal.pone.0198226.g003
Fig 4. Theaflavins are not inhibitors of HCV replication. Huh-7 cells expressing a HCV replicon containing a GFP-
tagged NS5A were incubated in the absence (DMSO) or presence of theaflavins at 25 μg/ml, or Bocebrevir at 1 μM, for
72 h. Cells were lysed and Western blot analysis was performed to detected NS5A-GFP and tubulin with specific
antibodies. Data are representative of 3 independent experiments.
https://doi.org/10.1371/journal.pone.0198226.g004
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In recent times, a number of promising natural products with anti-HCV activities have
been discovered [38–40]. They are of different origins and chemical structures and exert their
antiviral effects at different levels within the virus life cycle. While green tea polyphenols have
received the most attention in the past years, data presented in this study suggest that black tea
theaflavins may also be potent candidates for antiviral drug development particularly as entry
inhibitors against HCV. Our data show that TF3 has the most prominent effect against HCV
in comparison to TF1 and TF2. TF3 (EC50 = 2.2 μM) also is more potent than EGCG (EC50 =
10.6 μM) [14].
Our results clearly indicate that all the three derivatives of theaflavin act directly on viral
particles and may prevent cell surface attachment or receptor binding. The effect seems perma-
nent, not reversible, because after a 10-fold dilution of the compound in the presence of the
virus, the effect is similar to the one without dilution (Fig 5). In our earlier study cryo-electron
microscopy imaging showed that EGCG and delphinidin, an anthocyanidin, have a bulging
effect on HCV envelope of HCVpp [14]. We might speculate that theaflavins might have simi-
lar effect as both polyphenols shared close structural similarity. However, the exact mechanism
of action of theaflavins on HCV infection needs further studies.
TF3 seems to be most promising candidate against HCV and its efficacy may be attributed
to the presence of double galloyl moiety. The same has been found for HSV-1 where TF3 was
reported to be most effective [18]. In contrast, the presence of the galloyl group in TF3 is not
necessary for antiviral properties against calcivirus where all three theaflavin derivatives have
similar efficacy [17]. To understand the role of functional groups and galloyl moiety, further
study is required through the approach of combinatorial and synthetic chemistry. It is interest-
ing to note that theaflavins and EGCG have been described to inactivate the same viruses,
HSV-1, HIV-1 and influenza virus [18–20,41]. Taken together with the results presented here,
Fig 5. Theaflavins act on the viral particles prior inoculation. HCV virus stock was pre-incubated with 25 μg/ml of
theaflavins for 1 h before inoculation, and then the mixture was diluted 10 times before being used for the inoculation,
leading to a final concentration of theaflavins of 2.5 μg/ml (25 -> 2.5 μg/ml). In parallel, Huh-7 cells were inoculated
with HCV in the presence of theaflavins either at 2.5 or 25 μg/ml. Cells were fixed and subjected to
immunofluorescence to quantify infected cells as described above. Data are normalized to the DMSO, which is
expressed as 100% infection. The results are presented as means ± SEM of three independent experiments performed
in triplicate.
https://doi.org/10.1371/journal.pone.0198226.g005
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Fig 6. Theaflavins inhibit cell-to-cell spread. Huh-7 cells were inoculated with HCV JFH-1 for 2 h. Inoculum was
replaced by medium containing mAb 3/11 neutralizing antibody to prevent extracellular propagation. Theaflavins at
25 μg/ml or EGCG at 50 μM were added in the medium after inoculation. Cells were fixed 72 h after infection and
subjected to immunofluorescence detection of E1 HCV envelope protein revealed with a Cy3-conjugated goat anti-
mouse secondary antibody (red). Nuclei were stained with DAPI (blue). Representative images of each condition are
shown. Graph represents the number of cells/focus of 3 independent fields of three independent wells. Error bars
represent SD. Data are representative of 3 independent experiments. Statistical analysis were performed with the
Kruskal Wallis nonparametric test followed by a Dunn’s multicomparison post hoc test. ��, P = 0.009; ���, P< 0.0001.
https://doi.org/10.1371/journal.pone.0198226.g006
Fig 7. Theaflavins can be used in combination with DAA. Huh-7 cells were inoculated with HCV JFH-1 in the
presence of TF3 at given concentrations. Inoculum was removed and replaced by medium containing or not either
Daclatasvir at 6 pM or Sofosbuvir at 400 nM. Cells were fixed at 30 h post infection and subjected to
immunofluorescent detection of E1 envelope protein. Results are expressed as mean +/- SEM (error bars) of 3
independent experiments performed in triplicate. Data are normalized to DMSO, which is expressed as 100%
infection.
https://doi.org/10.1371/journal.pone.0198226.g007
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it seems that these polyphenols from tea, black or green, have a very specific mode of action on
enveloped viruses that could be more exploited in the context of antiviral therapy.
A future prospect of our study may be to determine the bioavailability of theaflavins in
human liver. Henning et al performed study on liver tissue of mice after black tea consump-
tion and showed that theaflavin relative absorption in liver is twice higher than EGCG [42].
TF1 concentration in mice liver is estimated at 0.4 nmol g-1 tissue, approximately 0.4 μM. In
contrast, TF2 and TF3 are poorly detected. Theaflavin content may vary from one tea to
another. It has been shown that Assam black tea contains more theaflavins than Darjeeling
tea, and particularly TF3 (125.9 and 26.8 μg/ml respectively) [43], which could lead to
higher relative absorption. Even if the tissue concentrations of theaflavins are lower than
their active concentrations, their use in combination with other DAA might reduce their
EC50 as shown in Fig 7. In this combination study, EC50 of TF3 is reduced in the presence of
Sofosbuvir or Daclatasvir to a concentration of approximately 0.3 μM. Taken together, these
results may be of crucial importance in developing a prophylactic drug for HCV risk group
population.
In conclusion, the present study identified theaflavins as new entry inhibitors of HCV infec-
tion. Their pan-genotypic action and ability to inhibit cell-to-cell spread are major advantages
for further evaluation for drug development, as well as their efficacy in combination with
actual antiviral therapy. Moreover, their ease of extracting, availability and popularity of tea as
a drink make them interesting candidate as entry inhibitors against HCV infection.
Supporting information
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